DRA Consultants Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 1:20 pm

Quick Insight

DRA Consultants Ltd, operating in the project consultancy/turnkey sector, currently trades at a price of 20.2 with a market cap of 22.2 Cr. The company's P/E ratio stands at 8.25, indicating a potentially undervalued stock based on earnings. With an ROE of 8.55% and ROCE of 12.3%, DRA shows decent profitability and efficient capital utilization. A healthy OPM of 18.15% reflects strong operational efficiency. The firm's low P/BV ratio of 0.83x suggests a possible bargain for investors. Additionally, DRA's comfortable interest coverage ratio of 17.70x indicates a low default risk. Overall, these metrics indicate DRA Consultants Ltd as a promising investment opportunity in the project consultancy sector.

Competitors of DRA Consultants Ltd

All Competitor Stocks of DRA Consultants Ltd

Quarterly Result

Last Updated: May 31, 2025, 6:15 am

Below is a detailed analysis of the quarterly data for DRA Consultants Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 12.34 Cr.. The value appears strong and on an upward trend. It has increased from 9.12 Cr. (Sep 2024) to 12.34 Cr., marking an increase of 3.22 Cr..
• For Expenses, as of Mar 2025, the value is 10.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.42 Cr. (Sep 2024) to 10.10 Cr., marking an increase of 2.68 Cr..
• For Operating Profit, as of Mar 2025, the value is 2.24 Cr.. The value appears strong and on an upward trend. It has increased from 1.70 Cr. (Sep 2024) to 2.24 Cr., marking an increase of 0.54 Cr..
• For OPM %, as of Mar 2025, the value is 18.15%. The value appears to be declining and may need further review. It has decreased from 18.64% (Sep 2024) to 18.15%, marking a decrease of 0.49%.
• For Other Income, as of Mar 2025, the value is 0.69 Cr.. The value appears strong and on an upward trend. It has increased from 0.15 Cr. (Sep 2024) to 0.69 Cr., marking an increase of 0.54 Cr..
• For Interest, as of Mar 2025, the value is 0.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Sep 2024) to 0.18 Cr., marking an increase of 0.09 Cr..
• For Depreciation, as of Mar 2025, the value is 0.47 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.42 Cr. (Sep 2024) to 0.47 Cr., marking an increase of 0.05 Cr..
• For Profit before tax, as of Mar 2025, the value is 2.28 Cr.. The value appears strong and on an upward trend. It has increased from 1.34 Cr. (Sep 2024) to 2.28 Cr., marking an increase of 0.94 Cr..
• For Tax %, as of Mar 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.12% (Sep 2024) to 25.00%, marking a decrease of 1.12%.
• For Net Profit, as of Mar 2025, the value is 1.70 Cr.. The value appears strong and on an upward trend. It has increased from 0.99 Cr. (Sep 2024) to 1.70 Cr., marking an increase of 0.71 Cr..
• For EPS in Rs, as of Mar 2025, the value is 1.55. The value appears strong and on an upward trend. It has increased from 0.90 (Sep 2024) to 1.55, marking an increase of 0.65.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 1:45 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:25 pm

Below is a detailed analysis of the balance sheet data for DRA Consultants Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 10.97 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.97 Cr..
• For Reserves, as of Mar 2025, the value is 21.85 Cr.. The value appears strong and on an upward trend. It has increased from 19.16 Cr. (Mar 2024) to 21.85 Cr., marking an increase of 2.69 Cr..
• For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 2.87 Cr.. The value appears to be improving (decreasing). It has decreased from 3.82 Cr. (Mar 2024) to 2.87 Cr., marking a decrease of 0.95 Cr..
• For Total Liabilities, as of Mar 2025, the value is 35.69 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 33.95 Cr. (Mar 2024) to 35.69 Cr., marking an increase of 1.74 Cr..
• For Fixed Assets, as of Mar 2025, the value is 6.99 Cr.. The value appears to be declining and may need further review. It has decreased from 7.26 Cr. (Mar 2024) to 6.99 Cr., marking a decrease of 0.27 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 10.23 Cr.. The value appears to be declining and may need further review. It has decreased from 10.37 Cr. (Mar 2024) to 10.23 Cr., marking a decrease of 0.14 Cr..
• For Other Assets, as of Mar 2025, the value is 18.47 Cr.. The value appears strong and on an upward trend. It has increased from 16.32 Cr. (Mar 2024) to 18.47 Cr., marking an increase of 2.15 Cr..
• For Total Assets, as of Mar 2025, the value is 35.69 Cr.. The value appears strong and on an upward trend. It has increased from 33.95 Cr. (Mar 2024) to 35.69 Cr., marking an increase of 1.74 Cr..

Notably, the Reserves (21.85 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for DRA Consultants Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 2.45. This value is below the healthy minimum of 5. It has increased from 2.17 (Mar 24) to 2.45, marking an increase of 0.28.
• For Diluted EPS (Rs.), as of Mar 25, the value is 2.45. This value is below the healthy minimum of 5. It has increased from 2.17 (Mar 24) to 2.45, marking an increase of 0.28.
• For Cash EPS (Rs.), as of Mar 25, the value is 3.27. This value is within the healthy range. It has increased from 2.82 (Mar 24) to 3.27, marking an increase of 0.45.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 29.92. It has increased from 27.47 (Mar 24) to 29.92, marking an increase of 2.45.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 29.92. It has increased from 27.47 (Mar 24) to 29.92, marking an increase of 2.45.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 19.56. It has increased from 17.89 (Mar 24) to 19.56, marking an increase of 1.67.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 4.36. This value is within the healthy range. It has increased from 3.63 (Mar 24) to 4.36, marking an increase of 0.73.
• For PBIT / Share (Rs.), as of Mar 25, the value is 3.54. This value is within the healthy range. It has increased from 2.98 (Mar 24) to 3.54, marking an increase of 0.56.
• For PBT / Share (Rs.), as of Mar 25, the value is 3.29. This value is within the healthy range. It has increased from 2.81 (Mar 24) to 3.29, marking an increase of 0.48.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 2.45. This value is within the healthy range. It has increased from 2.17 (Mar 24) to 2.45, marking an increase of 0.28.
• For PBDIT Margin (%), as of Mar 25, the value is 22.27. This value is within the healthy range. It has increased from 20.30 (Mar 24) to 22.27, marking an increase of 1.97.
• For PBIT Margin (%), as of Mar 25, the value is 18.08. This value is within the healthy range. It has increased from 16.67 (Mar 24) to 18.08, marking an increase of 1.41.
• For PBT Margin (%), as of Mar 25, the value is 16.82. This value is within the healthy range. It has increased from 15.73 (Mar 24) to 16.82, marking an increase of 1.09.
• For Net Profit Margin (%), as of Mar 25, the value is 12.54. This value exceeds the healthy maximum of 10. It has increased from 12.12 (Mar 24) to 12.54, marking an increase of 0.42.
• For Return on Networth / Equity (%), as of Mar 25, the value is 8.20. This value is below the healthy minimum of 15. It has increased from 7.90 (Mar 24) to 8.20, marking an increase of 0.30.
• For Return on Capital Employeed (%), as of Mar 25, the value is 11.82. This value is within the healthy range. It has increased from 10.86 (Mar 24) to 11.82, marking an increase of 0.96.
• For Return On Assets (%), as of Mar 25, the value is 7.54. This value is within the healthy range. It has increased from 7.01 (Mar 24) to 7.54, marking an increase of 0.53.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.61. It has increased from 0.60 (Mar 24) to 0.61, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 5.98. This value exceeds the healthy maximum of 3. It has increased from 3.96 (Mar 24) to 5.98, marking an increase of 2.02.
• For Quick Ratio (X), as of Mar 25, the value is 5.98. This value exceeds the healthy maximum of 2. It has increased from 3.96 (Mar 24) to 5.98, marking an increase of 2.02.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 17.70. This value is within the healthy range. It has decreased from 21.45 (Mar 24) to 17.70, marking a decrease of 3.75.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 10.97. This value is within the healthy range. It has decreased from 13.81 (Mar 24) to 10.97, marking a decrease of 2.84.
• For Enterprise Value (Cr.), as of Mar 25, the value is 23.32. It has decreased from 25.16 (Mar 24) to 23.32, marking a decrease of 1.84.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.09. This value is within the healthy range. It has decreased from 1.28 (Mar 24) to 1.09, marking a decrease of 0.19.
• For EV / EBITDA (X), as of Mar 25, the value is 4.88. This value is below the healthy minimum of 5. It has decreased from 6.31 (Mar 24) to 4.88, marking a decrease of 1.43.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.27. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.27, marking a decrease of 0.13.
• For Price / BV (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 0.91 (Mar 24) to 0.83, marking a decrease of 0.08.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.27. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.27, marking a decrease of 0.13.
• For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has increased from 0.08 (Mar 24) to 0.09, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness